Nasdaq · Biotech stocks database
RVMD (Revolution Medicines Inc.) stock: $190.95, $40.93B market cap, $3.94B cash, $36.99B EV, $47.67B fully diluted market cap. Next expected readout: Dec-26. Lead program: daraxonrasib (NSCLC (Non-small Cell Lung Cancer)), Phase 3. Data from Fully Diluted's biotech stocks database.
| Cash | $3,938.0M |
|---|---|
| Debt | $0.0M |
| Net cash | $3,938.0M |
| Enterprise value | $36,989.5M |
| Basic shares | 214.2M shares |
| Fully diluted shares | 249.6M shares |
| Fully diluted market cap | $47,667.0M |
| Cash per share | $18.38 |
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Loading RVMD daily closes…
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Feb 11 - Mar 25 | RMC-9805 | Phase 1 | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC) | — |
| May 12 - Jun 23 | RMC-6291 | Phase 1 | Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma | — |
| Jun 26 - Aug 7 | RMC-6236 | Phase 2 | Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma | — |
| Jul 12 - Aug 23 | RMC-6236 | Phase 2 | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC) | — |
| Jul 13 - Aug 24 | RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer | — |
| Jul 13 - Aug 24 | TNG462 | Phase 2 | PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC | — |
| Jan 12 - Feb 23 | daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC | 2027 |
| May 13 - Jun 24 | RMC-5127 | Phase 1 | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Adenocarcinoma | — |
| Jul 13 - Aug 24 | daraxonrasib | Phase 3 | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC | — |
| Jan 12 - Feb 23 | Elironrasib | Phase 2 | Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer; Pancreatic Ductal Adenocarcinoma | — |
| Feb 10 - Mar 24 | Zoldonrasib | Phase 3 | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC | — |
| Apr 12 - May 24 | daraxonrasib | Phase 3 | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC | — |
| Jun 12 - Jul 24 | Daraxonrasib | Phase 2 | Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC) | — |
| Jun 21 - Aug 2 | daraxonrasib | Phase 3 | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | — |
| Jul 13 - Aug 24 | SNV1521 | Phase 1 | Pancreatic Cancer; Pancreatic Acinar Carcinoma | — |
| Nov 12 - Dec 24 | zoldonrasib | Phase 3 | NSCLC; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer NSCLC | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.